Screener Summaries Updates Institutions Sign In More Updates › Leadership & Pay › IONS Leadership & Pay · Jun 8, 2026
Ionis Pharmaceuticals, Inc. announced the appointment of Ludwig N. Hantson to the Board of Directors, effective June… IONS Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. announced the appointment of Ludwig N. Hantson to the Board of Directors, effective June 4, 2026. The Company's 2026 Annual Meeting of Stockholders held on June 4, 2026, resulted in the approval of several proposals, including the election of directors and advisory vote on executive compensation, and amendments to equity incentive and employee stock purchase plans.
More from Ionis Pharmaceuticals Inc Roche reports sefaxersen achieved a 43.1% reduction in proteinuria in Phase 3 IgAN study Oct 23, 2026 FDA approves GSK's Hibsago for chronic hepatitis B, unlocking up to 12% royalties for Ionis Oct 21, 2026 Ionis and Roche report positive Phase 3 results for sefaxersen in primary IgA nephropathy Sep 23, 2026 On September 4, 2026, Ionis Pharmaceuticals announced that its partner Novartis reported the pelacarsen Phase 3… Sep 4, 2026 On September 3, 2026, the U.S. FDA approved ZANVASTRO (zilganersen) for the treatment of Alexander disease in… Sep 4, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
